30 Capsules (Silodosin 4mg)
Silodosin Capsule
Product Images NDC 46708-405
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 46708-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
30 Capsules (Silodosin 8mg)
Figure 1 (Silodosin Figur1)
Figure 2 (Silodosin Figur2)
The text provides information about the change observed in IPSS Total Score in a clinical study. The change was statistically significant (p<0.0001) and was observed between a group receiving Aries Placebo and a group receiving Silodosin Capsules 8 mg. The study was conducted over a period of 84 days and included a total of 357 participants. The last observation was carried forward (LOCF) for some participants.*
Figure 3 (Silodosin Figur3)
The text describes the change from baseline in IPSS (International Prostate Symptom Score) total score. The result shows significant improvement with silodosin capsules 8 mg compared to a placebo, with p-value less than 0.0001. The data is presented in a table with three columns - A (Placebo), @-e-e Silodosin Capsules 8 mg, and B 357, and four rows representing the change in IPSS total score at day 14, 28, and 84 (last observation carried forward).*
Figure 4 (Silodosin Figur4)
The text provides information about the change from the baseline in Qmax (maximum urinary flow rate) measured in mL/sec. The results show a statistically significant improvement with a p-value of less than 0.05 for Silodosin Capsules 8mg compared to Placebo. However, without additional context or explanation, it is difficult to understand the full implications of these findings.*
Figure 5 (Silodosin Figur5)
The text provides information on the change from baseline in maximum flow rate (Qmax) in mL/sec, with statistical significance indicated by "p<0.05" in comparison to placebo. The medication being evaluated is Silodosin Capsules 8 mg. There is also a graph with numerical values plotted for days 3, 14, 28, and 84, with "LOCF" likely referring to the last observation carried forward method.*
Structure (Silodosin Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
